Stockscreener 앱 받기
1.29
0.00%
0.00
시간 외 거래:
1.29
전일 마감가:
$1.29
열려 있는:
$1.3
하루 거래량:
78,540
Relative Volume:
0.51
시가총액:
$87.18M
수익:
-
순이익/손실:
$-64.20M
주가수익비율:
-0.60
EPS:
-2.15
순현금흐름:
$57,000
1주 성능:
+3.20%
1개월 성능:
+1.57%
6개월 성능:
-58.25%
1년 성능:
+0.00%
1일 변동 폭
$1.28
$1.36
1주일 범위
$1.16
$1.36
52주 변동 폭
$1.05
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
명칭
Climb Bio Inc
전화
1-866-857-2596
주소
20 WILLIAM STREET, WELLESLEY HILLS
CLYM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
1.29 | 84.47M | 0 | -64.20M | 57,000 | -2.15 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Outperform |
Climb Bio Inc 주식(CLYM)의 최신 뉴스
BNP Paribas Financial Markets Has $69,000 Stock Holdings in Climb Global Solutions, Inc. (NASDAQ:CLMB) - Defense World
This stealth AI supplier just leapfrogged 206 companies on the Fortune 500 - Fortune
Climb Bio (NASDAQ:CLYM) Upgraded at BTIG Research - Defense World
Are Wall Street Analysts Predicting Agilent Technologies Stock Will Climb or Sink? - MSN
Climb Bio Appoints Interim CFO Amid Leadership Change - TipRanks
2 S&P 500 Stocks to Buy Now On the Dip for Huge Upside - Yahoo Finance
BTIG sets Climb Bio stock Buy rating, $7 target By Investing.com - Investing.com Nigeria
BTIG sets Climb Bio stock Buy rating, $7 target - Investing.com
BioArctic shares climb on Q1 profit beat, boosted by Bristol payment - Investing.com Canada
Strong week for Access Bio (KOSDAQ:950130) shareholders doesn't alleviate pain of three-year loss - simplywall.st
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
What is Leerink Partnrs’ Estimate for Climb Bio Q2 Earnings? - Defense World
Climb Bio Awards $152K Stock Package to New Executive: Inside the Biotech's Latest Talent Investment - Stock Titan
Climb Bio Reports Increased Losses Amid Ongoing Development - TipRanks
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Tilray Brands Announces the Launch of XMG Atomic Sours: New THC Beverages and Edibles - The Manila Times
Climb Bio reports Q1 EPS (31c) vs (6c) last year - TipRanks
Climb Bio, Inc. SEC 10-Q Report - TradingView
Climb Bio (CLYM) Expected to Announce Earnings on Wednesday - Defense World
Life sciences firms climb after US and China agree to cut tariffs - TradingView
Exec Edge Launches Research Coverage with Initiation Notes on FL - GuruFocus
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB - Quantisnow
Market Update: Climb Bio Inc (CLYM) Sees Positive Movement, Closing at 1.21 - DWinneX
Stock Index Futures Climb on U.S.-China Trade Talk Optimism, Fed Rate Decision in Focus - The Globe and Mail
Astaxanthin Market Size to Climb USD 6.86 Billion by 2034 - Precedence Research
Dollar Falls and Gold Prices Climb on US Trade Uncertainty - The Globe and Mail
Jim Cramer on Netflix, Inc. (NFLX): ‘I Bet This One Can Continue to Climb Over the Long Haul’ - Yahoo Finance
Sugar Prices Slump on Expectations for Robust Global Supplies - The Globe and Mail
Kospi continues to climb gradually amid auto and bio gains - MSN
Stock market today: Dow extends longest win streak of 2025 as S&P 500, Nasdaq climb after latest tariff relief - Yahoo Finance
Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On? - Benzinga
F5 shares climb after earnings and revenue exceed analyst forecasts - SiliconANGLE
Hair Transplant System Market Expected to Climb to USD 44.24 Billion by 2032, Rising at 21.6% CAGR - openPR.com
Piper Sandler Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Virtual Cardiology Market Expected to Climb from USD 1.7 Billion in 2025 to USD 4.2 Billion by 2032 - openPR.com
Climb Bio Inc (NASDAQ: CLYM): On Track To A Higher Share Price - Stocksregister
Most active stocks: US stocks with the highest trading volume today - Yahoo
Sugar Prices Climb on Reduced Sugar Output in India - The Globe and Mail
UnitedHealth reports 'unusual and unacceptable' earnings as Medicare costs climb - Endpoints News
Netflix Stock Extends Recent Climb Ahead of Earnings Release - Investopedia
Enterprise AI Breakthrough: New Partnership Promises Hours-Fast Implementation for Fortune 500 Companies - Stock Titan
3,756 Shares in Climb Global Solutions, Inc. (NASDAQ:CLMB) Purchased by Arrowstreet Capital Limited Partnership - Defense World
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX - Yahoo Finance
Happy Joe’s, Sacco climb top industry Movers & Shakers list - Quad Cities Business Journal
CLYM stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
Climb Bio expands board with two new directors - Investing.com Australia
Climb Bio expands board with two new directors By Investing.com - Investing.com Canada
Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board - TipRanks
Climb Bio Expands Board with New Director Appointments - TipRanks
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
Climb Bio Inc (CLYM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.54%
자본화:
|
볼륨(24시간):